Updates are available Correction dated 2023-06-19
Click to view Correction: https://0-doi-org.brum.beds.ac.uk/10.1186/s10194-023-01610-4
-
Authors
Rasmussen, Nadja Bredo
Deligianni, Christina
Christensen, Casper Emil
Karlsson, William Kristian
Al-Khazali, Haidar Muhsen
Van de Casteele, Tom
Granhall, Charlotte
Amin, Faisal Mohammad
Ashina, Messoud
- License Information
-
More Information
Article History
Received: 4 April 2023
Accepted: 22 May 2023
First Online: 25 May 2023
Change Date: 19 June 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://0-doi-org.brum.beds.ac.uk/10.1186/s10194-023-01610-4
Declarations
:
: This study was designed in accordance with the Declaration of Helsinki and conducted in compliance with Good Clinical Practice and applicable regulatory requirements; all participants provided informed consent prior to participation.
: Not applicable.
: Dr. Karlsson has nothing to disclose. Dr. Rasmussen is a member of the editorial group G (neuromuscular diseases) of the neurological National Treatment Guidelines, Danish Neurological Society. Dr. Deligianni was supported by an IHS research fellowship grant and serves as a board member for the European Headache Federation. Dr. Christensen has received consulting fees and lecture honoraria from Teva; serves as a board member for the Danish Headache Society; and is a member of the steering committee for the Danish National Knowledge Center for Headache. Dr. Al-Khazali serves as a board member for the Danish Headache Society. Drs. Van de Casteele and Granhall are employees of Lundbeck. Dr. Amin has received personal fees from Eli Lilly, Lundbeck, Novartis, Pfizer and Teva; has received institutional payments from Novartis and Teva; has served on advisory boards for Pfizer, Eli Lilly, Lundbeck, Novartis and Teva; and serves as associate editor for Acta Neurologica Scandinavica, for Headache Medicine and for Frontiers in Pain Research, as junior associate editor for Cephalalgia and member of the editorial board of The Journal of Headache and Pain; is the President of Danish Headache Society and is a member of the European Headache Federation’s Board of Directors. Dr. Ashina is a principal investigator on clinical trials for AbbVie, Amgen, Eli Lilly, Lundbeck, Novartis and Teva; has received personal fees from AbbVie, Amgen, Eli Lilly, Lundbeck, Novartis, Pfizer and Teva; has received institutional research grants from Lundbeck Foundation, Novartis and Novo Nordisk Foundation; and serves as an Associate Editor of Cephalalgia, The Journal of Headache and Pain and Brain.
